02nd week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220008363 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-01-13 |
20220008364 | MACROCYCLIC COMPOUNDS AND USES THEREOF - This invention relates to macrocyclic cavity containing compounds and uses thereof in inhibiting a microbial signalling molecule or in reducing the amount of a microbial signalling molecule in a subject. The invention also relates to methods for inhibiting a microbial signalling molecule or for reducing the amount of a microbial signalling molecule in a subject by contacting a macrocyclic cavity-containing compound with said subject. | 2022-01-13 |
20220008365 | Treating Intraocular Retinoblastoma with Inhibitors of Histone Modification - Methods of treating a proliferative conditions of the eye, comprising administering to a patient a therapeutically effective amount of a composition that comprises a compound that inhibits the biological activity of a mammalian histone deacetylase (HDAC), or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier. | 2022-01-13 |
20220008366 | POTENTIATION OF HELMINTH TREATMENT - The present invention provides a method of treating liver fluke infections in a mammal in need of such treatment comprising administering an effective amount of diamphenethide in combination with an effective amount of clorsulon. | 2022-01-13 |
20220008367 | METHODS OF TREATING IDIOPATHIC HYPERSOMNIA - The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably a mixture of salts of oxybate (a mixed salt oxybate). | 2022-01-13 |
20220008368 | METHODS AND COMPOSITIONS RELATED TO TARGETING FFAR2 AND ILC3 POPULATIONS FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE - Described herein are methods, assays, and compositions and uses thereof related to treating, preventing, and detecting a gastrointestinal disease with an agent that targets Ffar2. The agents described herein can further increase populations of group 3 innate lymphoid cells (ILC3s) in the gut. | 2022-01-13 |
20220008369 | Use of Short Chain Fatty Acids in Cancer Prevention - The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions. | 2022-01-13 |
20220008370 | Systems and Methods Involving Non-Surgical Laser Treatment of a Fibrous Mass - Systems and methods for treating fibrous masses associated with conditions such as Morton's neuroma, stump neuroma, plantar fibroma, plantar fibromatosis, plantar fasciitis, plantar fasciopathy, and Achilles tendinopathy. According to implementation herein, exemplary methods may comprise non-surgically delivering electromagnetic energy to such fibrous masses in various ways. | 2022-01-13 |
20220008371 | BROAD SPECTRUM PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF VARIOUS INFECTIONS AND DISEASES AND METHODS OF USE - A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections, lice and dermatological diseases. | 2022-01-13 |
20220008372 | BACLOFEN FOR USE IN THE TOPICAL TREATMENT OF LOCALIZED MUSCULOSKELETAL PAIN - Methods of administering compounds of Baclofen and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, are provided for topical treatment and prevention of localized musculoskeletal pain. | 2022-01-13 |
20220008373 | COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to compositions, methods for preventing, treating and/or curing respiratory infections, such as infections caused by a coronavirus. | 2022-01-13 |
20220008374 | PHARMACEUTICAL COMPOSITIONS OF FUROSEMIDE AND USES THEREOF - A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof is disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and tris(hydroxymethyl)aminomethane. The furosemide is present in the pharmaceutical composition at a concentration from about 10 mg/mL to about 30 mg/mL and the tris(hydroxymethyl)aminomethane is present at a concentration of less than or equal to 40 mM. The pH value of the pharmaceutical composition is maintained between about 8.0 and about 8.5 for parenteral administration. | 2022-01-13 |
20220008375 | COMPOSITE FORMULATION AND USE THEREOF FOR PREPARING DRUGS FOR THE TREATMENT OF TUMOURS - The present disclosure relates to the field of biotechnology, and in particular, to a composite formulation and the use thereof for preparing a drug for treating a tumor. The effective components of the composite formulation of the present disclosure at least comprise a compound having a structural formula shown in Formula I and an EZH2 inhibitor. In terms of the clinical application for tumours, the present disclosure finds that a low dose of the compound having the structural formula shown in Formula I can enhance the therapeutic effects of the EZH2 inhibitor DZNEP and, when used in combination, can reduce the dosage of the EZH2 inhibitor DZNEP by ⅘ whilst ensuring pharmaceutical effectiveness, being an effective combination therapeutic solution. | 2022-01-13 |
20220008376 | INHIBITORS OF TYPE 3 SECRETION SYSTEM AND ANTIBIOTIC THERAPY - Type 3 Secretion System (T3 SS) inhibitors, tanshinones and tanshinone analogs, and methods of using the same for the treatment of disease are disclosed. The invention relates generally to antibiotic compounds and methods of treating or preventing bacterial infections using the same, and more particularly, but not exclusively, to compounds that inhibit biogenesis of the Type 3 Secretion System (T3 SS) needle, including tanshinone and tanshinone analogs, and methods of using the same. | 2022-01-13 |
20220008377 | COMPOSITION FOR PREVENTING OR TREATING CELLULAR SENESCENCE-RELATED DISEASES COMPRISING SALINOMYCIN AS EFFECTIVE COMPONENT - The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising salinomycin as an active ingredient, which acts differently depending on the type of senescent cells, and it was confirmed that salinomycin exhibits a senomorphics effect of restoring the function and morphology of fibroblasts and vascular endothelial cells in which senescence is induced and exhibits a senolytics effect of selectively killing aging-induced retinal pigmented epithelial cells, and exhibits a senomorphics effect of restoring the function and morphology of cells, and thus the salinomycin acts differently depending on the type of cells to effectively prevent or treat senile eye disease, tissue fibrosis disease, atherosclerosis, osteoarthritis, degenerative brain disease, chronic skin damage, obesity and diabetes caused by cellular aging and can be provided as a composition for life extension. | 2022-01-13 |
20220008378 | Formulations and methods - The present invention generally relates to formulations of and methods using one or more cannabis-derived compounds. In one aspect, the present invention provides a nanoemulsion. In addition to one or more cannabis-derived compounds (e.g., THC and/or CBD), the nanoemulsion typically includes at least one surfactant (e.g., Quillaja saponis), at least one encapsulator (e.g., modified food starch and/or maltodextrin), and at least one carrier (e.g., MCT coconut oil). Other suitable components such as one or more sweeteners (e.g., Xylitol) and/or one or more flow aids (e.g., Hydrophilic Fumed Silica having a Specific Surface Area (BET) between 175 m | 2022-01-13 |
20220008379 | STABILIZED CANNABINOID COMPOSITIONS AND METHODS OF PREPARATION THEREOF - This disclosure provides cannabinoid compositions with improved shelf-life stability, methods of use thereof, and methods of preparation thereof. | 2022-01-13 |
20220008380 | METHODS OF TREATING COVID-19 PATHOGENESIS - This disclosure provides methods for treating a SARS-CoV-2 infection in a subject comprising administering to the subject an effective amount of an inhibitor of COVID-induced RAS imbalance, that downregulates, for example, the Bradykinin system, the Renin-Angiotensin system, the hyaluronan synthesis pathway, or the fibrinogenesis pathway. | 2022-01-13 |
20220008381 | DILUTABLE FORMULATIONS OF CANNABINOIDS AND PROCESSES FOR THEIR PREPARATION - Provided are cannabinoid-loaded formulations, as well as processes for their preparation. | 2022-01-13 |
20220008382 | ALCOHOL ANTIDOTE - The present invention relates to the prevention and treatment of alcoholism, alcohol intoxication, and consequential symptoms and diseases associated with alcohol consumption, using specific flavonoids. | 2022-01-13 |
20220008383 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNOTHERAPIES - The present invention relates to compositions and methods of treating a subject having cancer by stimulating the subject's immune system and/or enhancing immunotherapies. Specifically, the present invention relates to methods of treating a subject by administering (1) a catechin ester or a derivative or metabolite thereof (e.g., EGCG) and (2) a nucleoside analogue (e.g., DAC), in combination with a checkpoint inhibitor or T-cell therapy. | 2022-01-13 |
20220008384 | COMPOSITION COMPRISING CAPSAICIN OR A CAPSACINOID FOR POSTOPERATIVE PAIN CONTROL - A composition comprising capsaicin or a capsacinoid is used in a method for postoperative pain control. The composition is administered to a site intended for surgery in a patient at least one day before surgery is actually performed. | 2022-01-13 |
20220008385 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER - The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker. | 2022-01-13 |
20220008386 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS - The present invention encompasses compounds of formula (I), wherein the groups R | 2022-01-13 |
20220008387 | METHODS FOR IMPROVED ENDOVASCULAR THROMBECTOMY USING 3,3'-DIINDOLYLMETHANE - Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3′-diindolylmethane. | 2022-01-13 |
20220008388 | COMBINATION OF GABOXADOL AND LITHIUM FOR THE TREATMENT OF PSYCHIATRIC DISORDERS - This disclosure reports on the discovery that low dose lithium can act in synergy with gaboxadol to enhance lithium's action on brain signaling activity. This combination of lithium and gaboxadol may greatly reduce the amount of lithium needed to treat many debilitating psychiatric disorders, such as bipolar disorder, depression, treatment resistant depression and suicidality, while reducing the often-serious side effects associated with high dose and chronic lithium treatment, especially nephrotoxicity, nephrogenic diabetes insipidus and chronic kidney disease. Co-administration of gaboxadol and lithium may also be useful for the treatment of refractory bipolar disorder, i.e. bipolar disorder which cannot be treated appropriately by administration of lithium alone. Gaboxadol may also prove useful as add-on therapy for the augmentation of the response to lithium in patients that do not respond to conventional lithium monotherapy. | 2022-01-13 |
20220008389 | METHODS OF TREATING RETT SYNDROME USING FENFLURAMINE - A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT | 2022-01-13 |
20220008390 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION - Disclosed in certain embodiments is a method for treating chronic pain with a hetero-substituted acetanilide compound that modulates the adenosine receptor. Disclosed in certain embodiments is a method for treating neuropathic pain (e.g., acute or chronic) with a hetero-substituted acetanilide compound that modulates the adenosine A3 receptor. Disclosed in certain embodiments is a method for treating inflammation (e.g., local inflammation or systemic inflammation), an inflammatory response, or an inflammatory condition with a hetero-substituted acetanilide compound. | 2022-01-13 |
20220008391 | NOVEL COMPOUNDS FOR CONTROLLING ARTHROPODS - The present invention relates to novel halogen-substituted compounds, to processes for their preparation and to their use for controlling animal pests, in particular arthropods and especially insects and arachnids. | 2022-01-13 |
20220008392 | METHODS OF TREATING CANCER - Methods of treating Mcl-1 dependent cancers are described herein. The methods can include determining whether the cancer is Bfl-1 positive, and administering an inhibitor of CDK9 to a patient if the cancer is Bfl-1 positive. | 2022-01-13 |
20220008393 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL - The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2022-01-13 |
20220008395 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS - Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R | 2022-01-13 |
20220008396 | COMPOSITIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS - As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms. | 2022-01-13 |
20220008397 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OCULAR NEOVASCULARISATION - The present invention relates to a pharmaceutical composition comprising tacrolimus and a semifluorinated alkane for use in the treatment of ocular neovascularisation. | 2022-01-13 |
20220008399 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES - Methods of treating a disease caused by a positive strand RNA virus. The methods include administering to a subject in need thereof an effective amount of a compound of Formula I or Formula II. | 2022-01-13 |
20220008400 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE - The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation. | 2022-01-13 |
20220008401 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASE WITH MATRIX METALLOPROTEINASE INHIBITORS - Disclosed in certain embodiments is a method of treating a pulmonary disease comprising administering a therapeutically effective amount of a Matrix Metalloproteinase (MMP) Inhibitor to a patient in need thereof wherein the pulmonary disease is selected from the group consisting of Acute Respiratory Distress Syndrome, Acute Lung Injury and Acute Inflammatory Injury, and compositions thereof. | 2022-01-13 |
20220008402 | INCREASED E-CADHERIN EXPRESSION OR ACTIVITY FOR THE TREATMENT OF INFLAMMATORY DISEASES - Provided herein are methods and systems employing agents that up-regulate E-cadherin, or E-cadherin agonists, for the treatment of inflammatory diseases, such as inflammatory bowel diseases (e.g., Crohn's disease). In certain embodiments, the agent employed is ML327, E-cadherin Up-regulator (ECU), or a compound of Formula I or II. | 2022-01-13 |
20220008403 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND - The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol | 2022-01-13 |
20220008404 | TREATMENT FOR SEVERE ACUTE RESPIRATORY ILLNESS ASSOCIATED WITH CORONAVIRUS - A method is provided for identifying a patient having a respiratory illness and administering to the patient a combination of an anti-inflammatory agent and a leukotriene inhibitor. The method may include treating respiratory illness associated with a coronavirus, and may it may further include reducing or preventing an inflammatory response or cytokine storm for those patients without impairing their immune response against the underlying pathogen. | 2022-01-13 |
20220008405 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS - The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent. | 2022-01-13 |
20220008406 | USE OF NUCIFERIN AND LOTUS LEAF EXTRACT IN THE PREPARATION OF A MEDICAMENT FOR TREATING ATROPHIC GASTRITIS AND/OR BLOCKING TRANSFORMATION OF GASTRITIS INTO CANCER - The present invention provides a use of a substance in the preparation of a product for treating chronic atrophic gastritis, protecting gastric mucosa, treating gastric precancerous lesions, blocking transformation of gastritis into cancer, and preventing occurrence of gastric cancer, the product being one selected from a medicament, a healthcare product and a foodstuff, and the substance being selected from the group consisting of: nuciferin, a nuciferin derivative, a lotus leaf extract, and a mixture of at least two selected from the above substances. The use includes at least one of treating chronic atrophic gastritis, protecting gastric mucosa, blocking transformation of gastritis into cancer, treating gastric precancerous lesions, and preventing occurrence of gastric cancer. In vitro experiments showed that nuciferin can block transformation of gastritis into cancer and cell proliferation. In vivo experiments showed that nuciferin and lotus leaf extract can treat atrophic gastritis in rats (especially chronic atrophic gastritis with intestinal metaplasia or dysplasia), protect rats from gastric mucosal damage and inhibit abnormal proliferation of gastrointestinal stem cells in | 2022-01-13 |
20220008407 | SMALL MOLECULES FOR INHIBITING CHEMOKINE ACTIVITY AND/OR CANCER CELLS GROWTH - Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or inhibiting a kinase and/or in treating a disease or disorder associated with an activity of a kinase, such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: | 2022-01-13 |
20220008408 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS - This invention relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to translesion synthesis (TLS) pathway. More particularly, this disclosure relates to small molecule inhibitors of TLS, methods of inhibiting TLS pathway with these compounds, and methods of treating diseases related to the TLS pathway. | 2022-01-13 |
20220008409 | CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE - Provided is a method for using a STAT3 inhibitor having a high antitumor effect and little side effects. The antitumor agent comprises a combination of a quinoline carboxamide derivative of formula (I) below or a pharmacologically acceptable salt thereof with one or more cancer molecular target drugs selected from the group consisting of an ALK inhibitor, an EGFR inhibitor, a multi kinase inhibitor, a HER2/EGFR inhibitor, an mTOR inhibitor, a BRAF inhibitor, a MEK inhibitor and a BCR-ABL inhibitor, wherein R | 2022-01-13 |
20220008410 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE - The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4. | 2022-01-13 |
20220008411 | TOLL-LIKE RECEPTOR 7 OR 8 AGONIST-CHOLESTEROL COMPLEX AND METHOD OF PREPARING SAME - The present disclosure relates to a toll-like receptor 7/8 agonist-cholesterol complex comprising: a cholesterol; and a toll-like receptor 7/8 agonist, wherein the cholesterol is linked to an active site of the toll-like receptor 7/8 agonist. | 2022-01-13 |
20220008412 | KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE - The present invention provides a method of treating depression disease in a treatment resistant patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, wherein the mucosal administration of the ketamine or dextromethorphan containing composition allows for the mucosal absorption of the composition eliminating the digestive tract of the patient for effecting a rapid acting antidepressant treatment of the treatment resistant patient. This method includes administering the composition to a patient's mucosal membrane of a respiratory tract, a genitourinary tract, an oral tract, or rectal tract of the patient. A pharmaceutically acceptable composition comprising ketamine or dextromethorphan and a vehicle is disclosed. A biomarker for identifying a depressive disease is set forth. | 2022-01-13 |
20220008413 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. | 2022-01-13 |
20220008414 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS - The present invention relates to a pharmaceutical composition for preventing or treating CMT disease, comprising histone deacetylase 6 inhibitor. The pharmaceutical composition according to the present invention has histone deacetylase 6 (HDAC6) inhibitory activity and thus is effective in preventing or treating CMT disease. | 2022-01-13 |
20220008416 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS - The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R | 2022-01-13 |
20220008417 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS - The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection. | 2022-01-13 |
20220008418 | Aminoquinoline Derivatives and Uses Thereof - Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome. | 2022-01-13 |
20220008419 | PHARMACEUTICAL COMPOSITION FOR TREATING DIFFUSE-TYPE GASTRIC CANCER - An object of the present invention is to provide a molecular targeted drug effective for diffuse gastric cancer. According to the present invention, there is provided a pharmaceutical composition for treating diffuse gastric cancer in a patient, which comprises an EGF receptor inhibitor having an ErbB1 inhibitory activity and an ErbB4 inhibitory activity. According to the present invention, there is provided the aforementioned pharmaceutical composition for use in a combination therapy with an anti-VEGF receptor 2 antibody and/or a cMET inhibitor. According to the present invention, there is provided a method for treating diffuse gastric cancer in a patient, which comprises the step of administering an EGF receptor inhibitor having an ErbB1 inhibitory activity and an ErbB4 inhibitory activity to the patient. | 2022-01-13 |
20220008420 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES - The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA. | 2022-01-13 |
20220008421 | TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY - A new therapeutic method in which a combination of an immune checkpoint inhibitor and a FOLFIRINOX therapy, a modified FOLFIRINOX therapy or a dose-reducing regimen of each of the therapies is effective to treat cancer, particularly cancer difficult to treat with conventional therapies such as pancreatic cancer. | 2022-01-13 |
20220008422 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease - The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof. | 2022-01-13 |
20220008423 | ORGANIC COMPOUNDS - The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms. | 2022-01-13 |
20220008424 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2022-01-13 |
20220008425 | Pharmaceutical Composition for Treating B-Cell Lymphoma - The present invention discloses a pharmaceutical composition for treating B-cell lymphoma, including a PI3K/AKT signaling pathway inhibitor and a chemotherapeutic drug, and further including a monoclonal antibody targeting CD20, such as rituximab. The pharmaceutical composition provided by the present invention is particularly suitable for the treatment of relapsed/refractory B-cell lymphoma. Given the critical role of cancer stem cells (CSCs) in the process of metastasis and drug resistance, the present invention proposes a new pro-differentiation therapy (PDT) strategy to cope with CSCs, i.e., to determine the decisive signaling pathway that maintains stem cell sternness and then promotes CSC differentiation by interfering with the pathway. Differentiated cells are eventually sensitive to conventional therapies, such as chemotherapy. In this situation, the PI3K/AKT signaling pathway inhibitor in combination with an R-CHOP regimen has a good effect on the treatment of drug-resistant diffuse large B-Cell lymphoma (DLBCL). | 2022-01-13 |
20220008426 | THERAPEUTIC COMBINATIONS COMPRISING A C-RAF INHIBITOR - The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination. | 2022-01-13 |
20220008427 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein. | 2022-01-13 |
20220008428 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND - The invention provides a compound of formula 1 | 2022-01-13 |
20220008429 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITION - A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization. | 2022-01-13 |
20220008430 | METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM - The disclosure provides methods of treating pain in a first subject in need thereof, comprising administering meloxicam to the first subject, wherein the first subject has a platelet dysfunction. In some embodiments, a closure time of platelets isolated from the first subject before administration of meloxicam is more prolonged than a closure time of platelets isolated from an otherwise similar subject without platelet dysfunction. In some embodiments, the closure time of platelets isolated from the first subject after administration of meloxicam is comparable to a closure time of platelets isolated from the first subject before administration of meloxicam. | 2022-01-13 |
20220008431 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES - The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels. | 2022-01-13 |
20220008432 | COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS - The present invention provides medicaments for use in treating and methods of treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, Sung cancer, non small-cell lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral squamous cell carcinoma, skin cancer, medul!ob!astoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, desmoid tumor, soft tissue sarcoma, or adenoid cystic carcinoma in a patient comprising combination therapy with 4,4,4-tri-fluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyemyl)-6-oxo-7H-pyrido[23-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyljbutanamide, or a pharmaceutically acceptable salt or hydrate thereof, and a PD-1 or a PD-L1 inhibitor selected from pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab. | 2022-01-13 |
20220008433 | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells - Methods for the generation of sensorineural hair cells, and more particularly to the use of epigenetic modulation of Atoh1 expression using a combination of Histone Lysine Demethylase (KDM) inhibitors and Wnt activators to generate sensorineural hair cells. | 2022-01-13 |
20220008434 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAME - The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same. | 2022-01-13 |
20220008435 | THERAPEUTIC, PREVENTIVE, OR IMPROVEMENT AGENT FOR INFLAMMATORY DISEASE AND ALLERGIC DISEASE - An object of the present invention is to provide a novel agent for treating, preventing or improving an inflammatory disease or an allergic disease. The present invention provides an agent for treating, preventing or improving an allergic disease, or as an agent for treating, preventing or improving an inflammatory disease or an allergic disease, comprising, as an active ingredient, (±) 5,6-dihydroxy-8Z,11Z,14Z,17Z-eicosatetraenoic acid (5,6-DiHETE). The inflammatory disease can be an inflammatory disease due to an increase of calcium concentration in vascular endothelial cells, and the inflammatory disease can be an inflammatory disease developed in a tissue or organ selected from the group consisting of digestive organs, circulatory organs, respiratory organs, urinary organs, genital organs, brain, skin, eyes, and fat. | 2022-01-13 |
20220008436 | TREPROSTINIL ADMINISTRATION BY INHALATION - Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil. | 2022-01-13 |
20220008437 | Use of prostaglandin E1 methyl ester in manufacture of vasodilator - The disclosure provides use of prostaglandin E1 methyl ester in the manufacture of a vasodilator. The prostaglandin E1 methyl ester has a structure represented by formula (I). the vasodilator is a drug for the treatment of microcirculation disorder, coronary heart disease, angina pectoris, heart failure, pulmonary heart disease, cerebral infarction, amniotic fluid embolism, or scleroderma. | 2022-01-13 |
20220008438 | TMA-PHT Complex (Olive Triterpenic and Polyphenolic Compounds) and Their Combinations, As A Group of Phytochemical Drug Compositions and/or Pharmaceutical Products for The Treatment of COVID-19 and Other Human and Animal Diseases and Conditions - TMA-PHT complex (olive triterpenic and polyphenolic compounds) and their combinations are used for preventing, alleviating, treating, or curing abnormal and/or pathological conditions of the living body, by such means as: (a) protecting the good health conditions of a living body by attracting, disabling, inhibiting, killing, modifying, repelling and/or retarding a virus or micro-organism in the case of preventing an infection (b) destroying a virus or a parasitic organism; (c) limiting the affecting of the disease by altering the physiology of the virus or parasite. In accordance with various embodiments, the present subject matter pertains to pharmaceutical drug compositions targeting various therapeutic objectives and their methods for preventing or treating Covid19 and/or other diseases and certain health conditions including the ones associated with inflammation and/or oxidative stress. | 2022-01-13 |
20220008439 | NOVEL USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF EPITHELIAL MICROBIAL INFECTIONS OF A FLUID CONTAINING ORGAN WITH A NATURAL EXTERIOR ORIFICE IN MAMMALS - The disclosure is directed to glucocorticoids for the treatment of epithelial microbial infections in fluid-containing organ having a natural exterior orifice in mammals; this new therapeutic use finds particular interest in the treatment of epithelial microbial infections of ear (such as otitis externa), udder (such as mastitis), and uterus (such as endometritis). | 2022-01-13 |
20220008440 | TEAT DISINFECTANT COMPOSITION - Antimicrobially effective compositions comprising lactic acid, salicylic acid, and at least one anionic surfactant are provided. The compositions are effective in controlling pathogen levels, particularly those commonly found on bovine teats to prevent or reduce the incidence of mastitis in lactating cows. In particular, the compositions possess germicidal and/or yeasticidal characteristics. Methods of using the antimicrobial compositions, as a part of a good milking routine, are also provided in which the compositions are applied to bovine teats. | 2022-01-13 |
20220008441 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day. | 2022-01-13 |
20220008442 | Phospholipid Ether Analogs for Imaging and Targeted Treatment of Pediatric Solid Tumors - It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: | 2022-01-13 |
20220008443 | Methods and Compositions for Prevention and Treatment of Apicomplexan Infections - Methods and compositions for preventing and/or treating diseases and conditions caused by certain apicomplexan infections are provided. The methods involve administering/providing to a subject one or more of tartrolon D and E, including isomers thereof. Exemplary apicomplexan infections that are prevented/treated by the compounds of the invention include those caused by | 2022-01-13 |
20220008444 | COMPOSITIONS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIZING ENTEROCOLITIS IN INFANTS AND YOUNG CHILDREN - The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children. | 2022-01-13 |
20220008445 | METHODS, COMPOSITIONS, AND KITS FOR TREATING OCULAR DISEASES - Provided herein are methods of treating an ocular disease associated with one or more nonsense mutation in a subject using one or more amino-glycosides and/or derivatives thereof. The pharmaceutical compositions and kits containing one or more aminoglycosides and/or derivatives thereof for treating the ocular disease are disclosed. | 2022-01-13 |
20220008446 | GLIFLOZINS AND A METHOD FOR THEIR DELIVERY DURING RESUSCITATION FROM CARDIAC ARREST TO IMPROVE SURVIVAL OUTCOMES - A method of performing cardiopulmonary resuscitation on a mammalian subject including the step of delivering an effective amount of a gliflozin solution during cardiac resuscitation through an intravenous or intraosseous route. | 2022-01-13 |
20220008447 | Rosacea Treatment Method - Topical application of a 2% (w/w) Delphinidin cream, twice per day, treats rosacea and maintains normal healthy skin in patients with rosacea. | 2022-01-13 |
20220008448 | METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS - Methods to inhibit FLT3 activity in a subject or a cell with an FLT3 mutation are provided. Methods of treating a hematologic cancer, such as acute myeloid leukemia, in a subject identified as having an FLT3 mutation, are also provided. | 2022-01-13 |
20220008449 | A METHOD OF MIMICKING BENEFITS OF DIETARY RESTRICTION BY TRANSIENTLY UPREGULATING ER STRESS RESPONSE - A role of molecular mechanisms determine the longevity of an organism, particularly, method of mimicking benefits of dietary restriction by transiently upregulating endoplasmic stress response. | 2022-01-13 |
20220008450 | ANTI-HEPATITIS B VIRUS AGENT - The present disclosure provides an anti-hepatitis B virus agent and a prophylactic or therapeutic agent for hepatitis B virus-related diseases, each comprising a nucleic acid analogue as an active ingredient. The problem can be solved by 2′-deoxy-2′-fluoro-β-2-fluoro-D-adenosine or its prodrug, or a pharmaceutically acceptable salt thereof, or a solvate thereof. | 2022-01-13 |
20220008451 | FLAVIN ADENINE DINUCLEOTIDE (FAD) FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER - The invention concerns Flavine adenine dinucleotide (FAD) for use in preventing and/or treating cancer. The FAD is favorably encapsulated at least partially in a particle with a vector to improve its absorption and distribution while limiting its destruction, in particular by blood hydrolases. The invention relates to the pharmaceutical field and more specifically to oncology or cancerology. | 2022-01-13 |
20220008452 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NASH, NAFLD, DIABETES, ATHEROSCLEROSIS, AND/OR OBESITY - In various aspects and embodiments the invention provides compositions and methods useful in the treatment of certain metabolic diseases, such as but not limited to NASH, NAFLD, diabetes, atherosclerosis, and/or obesity. | 2022-01-13 |
20220008453 | METHODS FOR TREATING ALZHEIMER'S DISEASE - Methods for the prevention or treatment of Alzheimer's disease in a human patient are disclosed comprising administering a hydroxypropyl-beta-cyclodextrin. | 2022-01-13 |
20220008454 | Silicic Acids for Use in the Treatment of Periodontitis - The oral administration of bioavailable silicic acid, such as choline-stabilized silicic acid during a period of at least 3 months daily leads to the prevention, inhibition and or treatment of periodontitis and peri-implantatis. The treatment is particularly suitable in combination with appropriate cleaning of the teeth and disinfecting the mouth, by one or more antiseptic and/or antimicrobial agent(s), as carried out at least once and suitably regularly, such as once per year, twice per year, four times per year or even every second month or every month. The treatment may be further enhanced by simultaneous administration of vitamins, trace elements, as well as by administration of a probioticum. Such additional agents may be applied separately, but are preferably incorporated in the formulation of bioavailable silicic acid. | 2022-01-13 |
20220008455 | Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic Plasticity - The present invention concerns a compound and composition for use in the preventive and/or curative treatment of diseases of the central nervous system characterised by a decline in neuronal plasticity, in particular a decline in synaptic plasticity, for example in the treatment of diseases of the central nervous system affecting cognitive processes such as learning, perception, attention, reasoning, language and/or memory, in the treatment of diseases of the central nervous system such as neurodegenerative diseases including Parkinson's disease, Alzheimer's disease and/or amyotrophic lateral sclerosis, in the treatment of diseases of the central nervous system responsible for mood disorders, hyperexcitability, hyperactivity and/or stress, and in the treatment of neurological conditions such as epilepsy, said compound being magnesium N-acetyl taurinate. | 2022-01-13 |
20220008456 | COMPOSITIONS AND METHODS TO DISINFECT, TREAT AND PREVENT MICROBIAL INFECTIONS - The present invention provides stable antimicrobial and disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The invention also provides on-demand storage and mixing vessels and methods for preparing and delivering on demand formulations. In addition, the invention provides antiviral, antibiotic and general antimicrobial uses, in vivo, on surfaces and via spray applications. | 2022-01-13 |
20220008457 | VANADIUM COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. A previously identified vanadium-containing compound, bis(maltolato)oxovanadium(IV) (BMOV), specifically provided for killing of SLC26A2 expressing cancer cells in a SLC26A2-dependent manner. The instant disclosure therefore provides for selecting and/or administering BMOV and related vanadium-containing compounds as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided. | 2022-01-13 |
20220008458 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE - Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 μg to about 4,000 μg of zinc, about 40 μg to about 400 μg of copper, from about 4 μg to about 90 μg of selenium, or from about 1 μg to about 80 μg of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided. | 2022-01-13 |
20220008459 | OPHTHALMIC FORMULATION AND METHODS OF USE - Provided herein are methods and compositions for an eye drop and medication. Accordingly, the eye drop and medication have the potential for the provision of and pioneering non-surgical treatment of eye conditions. | 2022-01-13 |
20220008461 | ANHYDROUS ANTIMICROBIAL TOPICAL FORMULATIONS AND METHODS OF USE THEREOF - Described herein are anhydrous antimicrobial topical formulations including metal nanoparticles and terpenes. Methods of use of the described formulations in wound treatment are also described. | 2022-01-13 |
20220008462 | SUBSTANCE FOR TREATING AND/OR PREVENTING TUMORS, AND DESIGN METHOD AND PREPARATION METHOD THEREOF - Provided is a method of designing and preparing a substance for treating and/or preventing a tumor, wherein, a stable structure corresponding to a tumor-related substance is used as the substance for treating and/or preventing the tumor. The essence of disease is the imbalance of organism structural system. The imbalance of the structure of substance in the organism structure system will cause diseases related to the substance. Disclosed is a method that the organism regulates genes or the expression of genes, restores the balance of the structures of substances in the organism structural system, and treats and/or prevents a disease related to the tumor, through the self-adaptation and self-organization of the structure system of the organism after recognizing the stable structure corresponding to the substance. | 2022-01-13 |
20220008463 | PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS - The present invention relates to a pharmaceutical composition for treating wounds, containing a silk protein and a plasma component as active ingredients. According to the present invention, wounds can be more effectively healed by using synergistic effects of a silk protein and a plasma component. | 2022-01-13 |
20220008464 | MODIFIED T CELL, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention relates to the field of gene editing and tumor immunotherapy. In particular, the invention relates to methods for preparing modified T cells, such as CAR-T cells, by gene editing, and modified T cells prepared by the methods and uses thereof. | 2022-01-13 |
20220008465 | METHODS OF DOSING ENGINEERED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES - Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects. | 2022-01-13 |
20220008466 | METHODS FOR EXPANSION OF NATURAL KILLER (NK) CELL SUBSET AND RELATED COMPOSITIONS AND METHODS - Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells. | 2022-01-13 |